Trial ID or NCT#

NCT01146054

Status

not recruiting iconNOT RECRUITING

Purpose

This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.

Official Title

Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jeffrey Norton, MD
Jeffrey Norton, MD
Surgical oncologist
Robert L. and Mary Ellenburg Professor of Surgery
Daniel Chang
Daniel Chang
Radiation oncologist
Sue and Bob McCollum Professor
Brendan C. Visser, MD
Brendan C. Visser, MD
Hepatobiliary surgeon, Pancreatic surgeon, Surgical oncologist
Associate Professor of Surgery (General Surgery)
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061